Loading clinical trials...
Loading clinical trials...
A Phase II Study of Nilotinib (AMN107) In TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral or Chronically Sun Damaged Melanoma
Conditions
Interventions
Nilotinib
Locations
8
United States
The Angeles Clinic and Research Institute
Santa Monica, California, United States
University of Colorado
Aurora, Colorado, United States
Moffitt Cancer Center
Tampa, Florida, United States
University of Chicago
Chicago, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
January 23, 2009
Primary Completion Date
April 1, 2011
Completion Date
March 1, 2014
Last Updated
November 15, 2018
NCT02621021
NCT07177937
NCT03050268
NCT05969860
NCT03340506
NCT04693377
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions